Treatment of active psoriatic arthritis - rapid review of TA 313 (NICE TA340)
NICE TA 340 - Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313)
MHRA Drug Safety Update - Ustekinumab (Stelara): risk of exfoliative dermatitis
Ustekinumab is recommended as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when: treatment with tumour necrosis factor (TNF) alpha inhibitors is contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis and golimumab for the treatment of psoriatic arthritis) or the person has had treatment with 1 or more TNF–alpha inhibitors.
Reason for decision: